Educational information, not financial advice or a personal recommendation. Not regulated by the FCA. Do your own research. Capital at risk.

Hims & Hers Health, Inc. (HIMS)

Healthcare Out of favour

Hims & Hers is a digital health platform that connects people with licensed medical professionals for treatments related to hair loss, skin care, and mental health.

$27.77

Is Hims & Hers Health, Inc. a good stock for a UK beginner?

The honest version: Hims & Hers is a digital health platform that connects people with licensed medical professionals for treatments related to hair loss, skin care, and mental health.

No rating · no target price · nothing for sale here
Price+50.0%
Priced in USD - as a UK investor your £ return also moves with the pound-to-dollar exchange rate, on top of the share price itself.
52-week range-36% past year
$27.77
Low $13.74High $66.20
Where today's price sits versus its past year - context, not a signal.
If you had put $1,000 into Hims & Hers Health, Inc.
$1,500+50%

Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.

Market cap: The company's total value on the stock market - share price times the number of shares. Big = 'large-cap', small = 'small-cap'.
$6.43B
Avg volume: How many shares change hands on a typical day. Higher means it's easy to buy or exit without moving the price.
18.95M
Day range: The lowest and highest price the shares traded at during the latest day.
$26.86 – $28.94
52-week range: The lowest and highest the shares have traded over the past year - a sense of how wide the swings have been.
$13.74 – $66.20
Dividend yield: The yearly dividend as a percentage of the share price - roughly the income you'd earn from dividends alone.
0.0%
Beta: How bumpy the share price is versus the whole market. Above 1 swings more than the market; below 1 is calmer. It's about the ride, not whether it goes up or down.
2.34
How bumpy is it?Beta: How bumpy the share price is versus the whole market. Above 1 swings more than the market; below 1 is calmer. It's about the ride, not whether it goes up or down. 2.34
Calm
Wild
Bumpier than the market

Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.

Why has it been moving?▼ -8% past week · ▼ -36% past year

Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.

The bull case

Becoming a dominant household name in digital health

The bear case

Regulatory changes impacting online prescription models

What does Hims & Hers Health, Inc. do?

The company operates an online shop and consultation service that makes it easier to get prescriptions for common personal health concerns delivered straight to your door. The cash rolls in from selling these subscription-based treatments and charging for the virtual doctor visits that facilitate them. Turning their high sales volume into consistent profit is the challenge, as they are currently hovering right around the break-even point.

VQGMI
Factor profile

On our factor screen it looks strongest on quality and value, and weakest on income.

Value: How cheap the stock looks versus profits, sales and assets (higher = cheaper). 27Quality: How profitable and financially healthy the company is (higher = stronger). 29Growth: How fast revenue and earnings are growing (higher = faster). 24Momentum: How the share price has been trending recently (higher = stronger recent run). 19Income: The dividend income on offer and how sustainable it looks (higher = more/steadier). 16
Quick checks
What's strong
  • Very high gross margins suggest a strong underlying business model
  • Convenient digital-first approach appeals to modern consumers
  • Subscription model provides a predictable stream of recurring revenue
What to watch
  • Value screens low (27/100)
  • Quality screens low (29/100)
  • Growth screens low (24/100)
  • Momentum screens low (19/100)
  • Income screens low (16/100)

What do Hims & Hers Health, Inc.'s numbers mean?

Gross margin
72.9%
This indicates that for every pound of sales, the company keeps over 72 pence after paying for the direct cost of the products, which is a very healthy sign.
Beta
2.3
A number above 1 means the share price tends to be much more jumpy and volatile than the wider stock market.
P/S
3.6
This compares the company's total market value to its annual sales, helping to see how much the market is paying for each pound of revenue generated.

How much money does Hims & Hers Health, Inc. make?

Revenue and profit by quarter, and how much of each sale turns into profit.

RevenueNet income
$0$154.45M$308.91M$463.36M$617.82MQ1 25Q2 25Q3 25Q4 25Q1 26
Gross margin
72.9%
Net margin
-0.6%
Return on equity
-2.7%

Does Hims & Hers Health, Inc. pay a dividend?

No - Hims & Hers Health, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.

More in Healthcare

Eli LillyWest Pharmaceutical Services, Inc.Incyte CorporationThe Cigna GroupZimmer Biomet Holdings, Inc.Moderna, Inc.Gilead Sciences, Inc.Regeneron Pharmaceuticals, Inc.

What are the scenarios for Hims & Hers Health, Inc.?

An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.

$57$28$12today · $28▲ Bull · $33• Base · $28▼ Bear · $22in 1 yearILLUSTRATIVE · NOT A PREDICTION OR PRICE TARGET
Bull
+15% to +25%Stronger than expected quarterly subscriber growth
Base
-5% to +5%Steady performance in line with current trends
Bear
-15% to -25%Increased marketing costs eating into margins

What are the pros and cons of Hims & Hers Health, Inc.?

3bull points
6bear points

How many points the write-up makes each way — a balance check, not a score or verdict.

The bull case3
  • Very high gross margins suggest a strong underlying business model
  • Convenient digital-first approach appeals to modern consumers
  • Subscription model provides a predictable stream of recurring revenue
The catch3
  • The company is not yet consistently profitable
  • High beta indicates the share price can be quite a rollercoaster
  • Revenue growth has slowed down recently
Key risks3
  • Changes in healthcare regulations could disrupt the online prescription process
  • Intense competition from both established pharmacies and new digital entrants
  • High reliance on marketing spend to acquire new customers
What would flip the thesis

The write-up's own warning lights — if these start happening, the case above changes.

Confidence: medium · data: USD · flags: pe, earnings_growth · Charts by TradingView Lightweight Charts™
Found this useful? The Almanac is free and ad-free - a coffee keeps it that way.Support →

Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →

This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.

Figures as of 2026-08-01. Prices may be delayed and numbers can go stale - always double-check before acting.